Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF‐I concentrations
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: OBJECTIVE We studied the relationship between plasma level of insulin‐like growth hormone I (IGF‐I), changes in lean body mass and in adipose mass, and adverse side‐effects during human growth hormone (hGH) treatment of elderly men who had low IGF‐I levels. DESIGN The first six months was a period of baseline observation. The subjects were then randomized into two groups so that during months 7–18, men in group I received hGH, and men in group II served as untreated controls. SUBJECTS Eighty‐three overtly healthy elderly men, who were selected because their plasma IGF‐I level was less than 0.35 units/ml. The men were randomly assigned in a ratio of three to one into group I (n= 62) or into group II (n= 21). MEASUREMENTS Plasma IGF‐I level was measured monthly. Lean body mass and adipose mass were measured every six months. RESULTS Fifteen men left the study during the baseline period because of personal reasons or intercurrent medical events. In those who received drug (group I), there were a number of adverse reactions which could have been related to the hGH therapy: carpal tunnel syndrome 10, gynaecomastia 4, and hyperglycaemia 3. In total there were 27 dropouts from group I and two dropouts from group II after the six‐month point, for a variety of medical and non‐medical reasons, the majority probably not related to hGH therapy. During the hGH treatment of group I, plasma IGF‐I increased from the range 0.10–0.35 units/ml into the range 0.5–2.2 units/ml. Among the 18 men who completed 12 months of hGH treatment without experiencing one of the three above‐noted presumed hGH side‐effects, mean and peak plasma IGF‐I during treatment were significantly lower than among the 13 men who experienced carpal tunnel syndrome or gynaecomastia (one subject had both) while on hGH. With one exception, neither carpal tunnel syndrome nor gynaecomastia occurred in any individual with a mean IGF‐I level less than 10 units/ml during hGH treatment. Twelve months of hGH treatment (group I) caused an increase in lean body mass to 106% of the initial baseline (month one of the protocol), and a reduction in adipose mass to 84% of the baseline. Meanwhile, the lean body mass of the untreated men in group II declined to 97% of the initial baseline. The body composition responses after 12 months of treatment in group I were larger in the men whose mean intra‐treatment IGF‐I level was 0.5–1.0 units/ ml, than in the men whose mean intra‐treatment IGF‐I level was 1.0–1.5 units/ml. CONCLUSIONS These observations show that when elderly men with low circulating IGF‐I concentrations are treated continuously with hGH, elevation of plasma IGF‐I above 10 units/ml is associated with a substantial frequency of carpal tunnel syndrome or gynaecomastia. It may be that the effects of the hormone in expanding lean body mass and reducing adipose mass can be achieved, and the side‐effects avoided, by maintaining the mean IGF‐I level in the range 0.5–1.0 units/ml.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Davidson, M. B. (1979) · Metabolism · doi:10.1016/0026-0495(79)90024-6 · Cited by 411
Cited by
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822
Anorexia of aging: physiologic and pathologic
Morley, J. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/66.4.760 · Cited by 763
Serum levels of insulin-like growth factor I and its binding proteins in health and disease
Juul, A. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00038-8 · Cited by 467
Blackman, M. R. (2002) · JAMA · doi:10.1001/jama.288.18.2282 · Cited by 455
Metadata
- Authors
- Cohn, L., Feller, A. G., Draper, M. W., Rudman, I. W., & Rudman, D.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1993-10
- Volume
- 39
- Issue
- 4
- Pages
- 417-425
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2158378127
- Cited by
- 139
- References
- 3
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF‐I concentrations. https://app.cochat.ai/papers/10.1111/j.1365-2265.1993.tb02388.x
- The paper
- Cohn, L., Feller, A. G., Draper, M. W., Rudman, I. W., & Rudman, D. (1993). Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF‐I concentrations. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.1993.tb02388.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.